EICHORCondition: Hepatocellular Carcinoma · Sponsor: Lukas Biomedical Inc.
This is an open-label, single arm, multicenter, Phase II clinical study to investigate the efficacy and safety profiles of autologous ATL administration in HCC patients after curative treatment. Among all the eligible patients, ratio of 7:2:1 for Stage I:II:IIIa of the HCC will be the enrolled strategy of the study to reflect the results of the previous study (Lee, Lee et al. 2015).
This description comes directly from the study's public registry record.
Eric Tang, M.D · +886-2-2950-0027 · service@lukas-biomedical.com
Always discuss trial participation with your own doctor first.
| Hualien Tzu Chi Hospital | Hualien City, Taiwan, Taiwan | Recruiting |
| Cardinal Tien Hospital | New Taipei City, Taiwan, Taiwan | Not Yet Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan, Taiwan | Recruiting |
| Taipei City Hospital, RENAI Branch | Taipei, Taiwan, Taiwan | Recruiting |
| E-Da Cancer Treatment Hospital | Kaohsiung City, Taiwan | Recruiting |
| Far Estern Memorial Hospital | New Taipei City, Taiwan | Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Not Yet Recruiting |
| Chi Mei Hospital, Liouying | Tainan, Taiwan | Not Yet Recruiting |
| Taipei Medical University Hospital | Taipei, Taiwan | Recruiting |
| Shin Kong Wu Ho Su Memorial Hospital | Taipei, Taiwan | Not Yet Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Recruiting |
| Tri-Service General Hospital | Taipei, Taiwan | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05304481